Specifying which patients should undergo cardiovascular surveillance following lymphoma treatment 

Jakub Svoboda, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, discusses the evolving landscape of cardiovascular surveillance in patients undergoing lymphoma treatment. He emphasizes the need for individualized approaches due to limited data on specific surveillance protocols tailored to each therapy. Dr Svoboda highlights the need for further research into therapies such as BTK inhibitors, immune checkpoint inhibitors, and CAR-T therapies to better understand their cardiovascular implications. This interview occurred at the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.